Clinical trials: Neurodegenerative Disorders
Optic, Atrophy, Hereditary, Leber
Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)
The goal of this clinical trial is to assess the effectiveness of GS010, a gene therapy, in improving the visual outcome in participants with Leber Hereditary Optic Neuropathy (LHON) due to the G11778A ND4 mitochondrial mutation…
- Trial name
- REVERSE (NCT02652780)
- Testing
- GS010
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 37 people
- Sponsor
- GenSight Biologics
Alzheimer's Disease
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).
- Trial name
- NCT00679627
- Testing
- Galantamine
- Where
- 95 sites in Czechia, Estonia and 10 more
- Volunteers
- 2,051 people
- Sponsor
- Janssen Research & Development, LLC
Parkinson's Disease
Long-term Effect of Low Frequency Stimulation on Aspiration and Freezing of Gait in PD With STN DBS
Our recent study (Xie et al, Neurology 2015; 84: 415-420) found that bilateral STN DBS of 60Hz, compared to the traditional 130Hz, decreased the aspiration frequency and swallowing difficulty, freezing of gait (FOG), and other…
- Trial name
- NCT02549859
- Testing
- Deep Brain Stimulation (DBS) at 60 Hz, Deep Brain Stimulation (DBS) at 130 Hz
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Chicago
Alzheimer Disease
A Study of LY3002813 in Participants With Alzheimer's Disease
The study will evaluate the safety of LY3002813 by looking at adverse events. The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT01837641
- Testing
- LY3002813-IV, LY3002813-SC
- Where
- 6 sites in United States, Japan
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Severe Alzheimer Disease
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.
- Trial name
- NCT03765762
- Testing
- GRF6019
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Alkahest, Inc.
Neurofibromatosis Type 1
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
This study is designed to define a dosing regimen and assess the pharmacokinetics(PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints.
- Trial name
- SPRINKLE (NCT05309668)
- Testing
- Selumetinib granule formulation, Selumetinib capsule formulation
- Where
- 16 sites in United States, Germany and 5 more
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Excessive Sleepiness, Parkinson Disease
A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
This study is a 4-week, multicenter, randomized, double-blind, placebo-controlled, ascending dose, 4-period crossover study designed to evaluate the safety, tolerability, efficacy, and PK of JZP-110 (75, 150, and 300 mg) in the…
- Trial name
- NCT03037203
- Testing
- JZP-110
- Where
- 25 sites in United States
- Volunteers
- 66 people
- Sponsor
- Jazz Pharmaceuticals
Frontal Lobe Dementia, Frontotemporal Lobe Dementia
Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
The primary objective of the study is to determine whether memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia.
- Conditions
- Frontal Lobe Dementia, Frontotemporal Lobe Dementia, Semantic Dementia
- Trial name
- NCT00545974
- Testing
- memantine
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- University of California, San Francisco
TTR-mediated Amyloidosis
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.
- Trial name
- NCT02292186
- Testing
- Revusiran (ALN-TTRSC)
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 25 people
- Sponsor
- Alnylam Pharmaceuticals
Myasthenia Gravis
Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis
This was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tolebrutinib compared with placebo in adult participants aged 18 to 85 years old with moderate-to-severe…
- Trial name
- URSA (NCT05132569)
- Testing
- Tolebrutininb
- Where
- 22 sites in United States, Canada and 7 more
- Volunteers
- 6 people
- Sponsor
- Sanofi
Chronic Traumatic Encephalopathy
18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.
- Trial name
- NCT02079766
- Testing
- florbetapir F 18, Flortaucipir F18
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Amyotrophic Lateral Sclerosis (ALS), Neuromuscular Diseases
Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease
This project seeks to investigate the effects of a single acute intermittent hypoxia (AIH) session on respiratory and non-respiratory motor function and EMG (electromyography) activity on patients with ALS (amyotrophic lateral…
- Trial name
- AIH-ALS (NCT03645031)
- Testing
- Acute Intermittent Hypoxia
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Florida
Nonmalignant Neoplasm, Tuberous Sclerosis
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
This research study is evaluating a drug called rapamycin as a possible treatment for the lumps (or tumors) that form in the kidneys, called angiomyolipomas, in people who have either TSC or LAM.
- Conditions
- Nonmalignant Neoplasm, Tuberous Sclerosis, Lymphangioleimyomatosis, Kidney Angiomyolipoma
- Trial name
- NCT00126672
- Testing
- Rapamycin
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
Alzheimer's Disease
A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease
The purpose of this study is to demonstrate that the change of attention measure is correlated with the changes of caregiver's burden after treatment with galantamine.
- Trial name
- NCT01734395
- Testing
- Galantamine
- Volunteers
- 1,882 people
- Sponsor
- Janssen Korea, Ltd., Korea
Alzheimer Disease, Mild Cognitive Impairment
Brain Energy Metabolism and Sleep in Adults
The three primary goals of this pilot will be followed by a secondary goal to test if dental intervention improves brain health in terms of sleep and cognition. The primary and secondary goals are 1.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Cognitive Change, Energy Metabolism
- Trial name
- NCT03929302
- Testing
- MyTAP oral appliance plus mouth shield
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas at Dallas
Parkinson Disease
A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics and catechol-O-methyltransferase (COMT) activity of BIA 9-1067 in healthy male subjects after single oral ascending doses.
- Trial name
- NCT01520727
- Testing
- BIA 9-1067
- Where
- France
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
In-home Cycling for Individuals With PD: Feasibility
This study will examine the influence of social support on exercise frequency, duration, quality of life, and overall activity level.
- Trial name
- NCT04300023
- Testing
- Social Cycling Group
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Wisconsin, Madison
Neurofibromatosis Type 1
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Treatment Overview This phase II study will evaluate the activity of sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas that have the potential to cause significant morbidity.
- Trial name
- Protocol 102 (NCT00634270)
- Testing
- Sirolimus
- Where
- 9 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Alabama at Birmingham
Parkinson Disease, Parkinson's Disease
REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study
Ropinirole Hydrochloride (ROP) was granted approval for the treatment of Parkinson's Disease (PD) on 20 October 2006. ROP is expected to be used for a long term in clinical practice.
- Trial name
- NCT00485069
- Testing
- ROP, ROP+L-Dopa
- Where
- 22 sites in Japan
- Volunteers
- 123 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease, Depression
SAM-e for the Treatment of Depression in Patients With Parkinson's Disease
This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).
- Trial name
- NCT00070941
- Testing
- SAM-e, oral escitalopram
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- NYU Langone Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.